Offsetting impairment loss on shares of the Chinese sales subsidiary with gain on sale of investment securities
First written in FY2019-Q3. 1 of 8 entries say "Restated". Latest entry: FY2025.
0 other companies' latest entry also says "Dropped".
- FY2025DroppedAnnual report
「Gain on sale of investment securities 50,677 -」
The gain on sale of investment securities recorded in the previous fiscal year was not recorded in the current fiscal year. - FY2024Gain on sale of investment securities decreasedAnnual report
「Gain on sale of investment securities 55,686 50,677」
The gain on sale of investment securities decreased from ¥56 million in the previous fiscal year to ¥51 million. - FY2024-Q3Gain on sale of investment securities continues but declinesAnnual report
「Gain on sale of investment securities 55,686 50,677」
The company recorded a ¥51 million gain on sale of investment securities for the cumulative third quarter, down from ¥56 million in the same period of the previous year. - FY2023-Q2Recognition of Gains on Sales of Investment SecuritiesAnnual report
「Gain on sale of investment securities - 55,686」
The company recorded a ¥55.7 million gain on sale of investment securities as an extraordinary gain during the cumulative second quarter. - FY2021Impairment loss on investment securities recognized for the full fiscal yearAnnual report
「During the consolidated fiscal year, the company recognized an impairment loss of ¥9.810 million on securities, consisting of shares classified as other securities.」
The company recorded a ¥9.81 million impairment loss on investment securities as an extraordinary loss for the full fiscal year. - FY2021-Q3Recorded an impairment loss on investment securitiesAnnual report
「Impairment loss on investment securities - 9,288」
The company recorded a ¥9 million impairment loss on investment securities as an extraordinary loss during the cumulative third quarter. - FY2019RestatedAnnual report
「During the consolidated fiscal year, the company recognized impairment losses of ¥132.701 million on securities, comprising ¥40.867 million on shares classified as other securities and ¥91.833 million on shares of unconsolidated subsidiaries.」
The company recognized impairment losses of ¥132.7 million on securities, including shares of Chinese unconsolidated subsidiaries, while also recording a ¥135.7 million gain on sale of investment securities, and explained that the impact on profit or loss was limited. - FY2019-Q3First statedAnnual report
「Although the company recorded an impairment loss on shares of its Chinese sales subsidiary as an extraordinary loss, it also recorded a gain on sale of investment securities as an extraordinary gain that exceeded the loss, resulting in no impact on profit or loss.」
The company recorded an impairment loss on shares of its Chinese sales subsidiary, but also recorded a gain on sale of investment securities that exceeded the loss, and explained that there was no impact on profit or loss.